Accessibility Menu
Ptc Therapeutics Stock Quote

Ptc Therapeutics (NASDAQ: PTCT)

$66.52
(-1.0%)
-0.65
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$66.52
Daily Change
(-1.0%) $0.65
Day's Range
$66.02 - $67.58
Previous Close
$66.52
Open
$67.01
Beta
0.99
Volume
543,831
Average Volume
1,314,218
Market Cap
5.3B
Market Cap / Employee
$67.17M
52wk Range
$35.95 - $69.48
Revenue
-
Gross Margin
0.96%
Dividend Yield
N/A
EPS
$6.97
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ptc Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PTCT+69.18%+28.02%+5.06%+303%
S&P+14.5%+93.32%+14.09%+322%

Ptc Therapeutics Company Info

PTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$178.88M-4.2%
Gross Profit$163.39M-2.9%
Gross Margin91.35%1.2%
Market Cap$3.87B65.0%
Market Cap / Employee$4.12M0.0%
Employees939-5.6%
Net Income-$64.85M34.6%
EBITDA-$27.28M-3.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$1.02B55.4%
Accounts Receivable$196.13M4.8%
Inventory34.17.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$371.08M-2.2%
Short Term Debt$17.08M6.7%

Ratios

Q2 2025YOY Change
Return On Assets27.65%57.1%
Return On Invested Capital-30.15%15.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$59.65M6.9%
Operating Free Cash Flow-$58.33M18.4%

Valuation

MetricQ1 2025Q2 2025YoY Change
Price to Earnings7.837.00-
Price to Book-2.91-3.29-3.61-20.83694.34%
Price to Sales3.174.322.482.16-17.00%
Price to Tangible Book Value-2.05-2.37-3.05-10.01457.85%
Price to Free Cash Flow TTM6.355.47-
Enterprise Value to EBITDA-49.27-300.262.83-81.2429.81%
Free Cash Flow Yield15.7%18.3%-
Total Debt$400.21M$389.30M$389.62M$388.17M-1.86%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.